Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (December 2013)

27 slides from Cadence Pharmaceuticals's investor presentation, Dec 16, 2013

  1. Slide 1: Corporate Presentation

    EXHIBIT 99.1 Improving the lives of hospitalized patients Corporate Presentation December 16, 2013

  2. Slide 2: Caution on forward-looking statements

    Caution on forward-looking statements This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. market opportunity for OFIRMEV; our financial estimates and pr

  3. Slide 3: Investment highlights

    Investment highlights • Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting – OFIRMEV® (acetaminophen) injection –Indicated for use in adults and children >2yrs for the: • Management of mild to moderate pain • Manag

  4. Slide 4: OFIRMEV (acetaminophen) injection

    OFIRMEV® (acetaminophen) injection • Proprietary IV acetaminophen formulation • First and only IV formulation of acetaminophen approved in the United States • New class of IV medication – non-narcotic / opioid – non-NSAID • Same formulation of IV acetaminophen marketed by BMY in Europe since 2002 as

  5. Slide 5: Strong foundation for commercial success

    Strong foundation for commercial success (1) • Significant pain relief (1)* Effective Pain • Reduced opioid consumption Control (1),(2) • Improved patient satisfaction • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior territory Expe

  6. Slide 6: Label supports the message

    Label supports the message Message Significant pain relief Reduced opioid consumption Improved patient satisfaction Established safety profile Broad Label Mild to moderate pain Moderate to severe pain with adjunctive opioids Treatment of fever Adults and children 2 and older 6

  7. Slide 7: Limitations of other IV pain therapies

    Limitations of other IV pain therapies Opioids NSAIDs Sedation Bleeding Nausea GI complications Vomiting Kidney complications Constipation Cardiovascular risks Headache Cognitive impairment Respiratory depression Prolonged recovery Limited use Increased length of stay Higher costs to the institution

  8. Slide 8: Multimodal analgesia is becoming standard

    Multimodal analgesia is becoming standard Historical Emerging Pain Intensity US Approach US Approach IV acetaminophen Severe Opioids + opioids IV acetaminophen Moderate Opioids + opioids, if necessary Mild Opioids IV acetaminophen 8

  9. Slide 9: Strong commercial acceptance

    Strong commercial acceptance • Rapid formulary adoption – On formulary in over 2,350 hospitals* – Minimal restrictions • Strong physician support and early experience positive – OFIRMEV physician market research:** • 97% of physicians surveyed reported that OFIRMEV’s efficacy met or exceeded their e

  10. Slide 10: Strong OFIRMEV sales growth

    Strong OFIRMEV® sales growth • WAC sales reported to be $11.8M for October 2013 • Monthly vial sales of 895K in October 2013 OFIRMEV Monthly Sales 14.0 600 12.0 500 10.0 400 8.0 300 6.0 200 4.0 100 2.0 0.0 - Monthly Sales ($M) Sales/Day ($ 000's) 10 Source: Source Healthcare Analytics, Source® PHAST

  11. Slide 11: Historical account growth metrics

    Historical account growth metrics Customer Base • Growth in customer base – Number of unique customer accounts increased to over 4,600 in Q3 2013 – Number of repeat customers grew to over 3,900 in Q3 2013 and represents approximately 85% of all customers • Increase in frequency of product use – Hosp

  12. Slide 12: Broad adoption

    Broad adoption • As of end of Q3 2013: – Over 2,350 hospital formulary approvals – Over 4,600 accounts have ordered OFIRMEV 12

  13. Slide 13: Significant growth in new customers

    Significant growth in new customers 5,000 Cumulative Accounts Ordering OFIRMEV® 4,500 4,000 3,500 3,000 2,500 Multiple Order Single Order 2,000 1,500 1,000 500 0 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Significant growth in new and repeat customers each quarter • Approximat

  14. Slide 14: Growing average order size

    Growing average order size Average Order Size/Quarter (vials) 105 100 96 92 85 79 75 65 57 50 40 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 14

  15. Slide 15: Growth drivers

    Growth drivers • Expanding physician user base* – Market research indicates growing user base in targeted accounts – Proportion of surgeons using OFIRMEV in targeted accounts has tripled in less than 2 years • Increasing share of surgical patients – Data from Premier healthcare alliance indicates co

  16. Slide 16: Market research: increasing prescriber base

    Market research: increasing prescriber base More physicians in targeted accounts are using OFIRMEV® Physicians Currently Using OFIRMEV 84% 87% 76% 65% 66% 59% 44% 23% n=120 n=122 n=61 n=54 n=279 n=344 n=236 n=137 Anesthesiologist Surgeon (General & Orthopedic) Sept '11 May '12 Dec '12 July '13 Sept

  17. Slide 17: Increasing share of surgical patients

    Increasing share of surgical patients OFIRMEV ® Share of US Hospital Surgical Procedures (Premier Healthcare Alliance Database) 16.0% 14.0% 12.0% 10.0% 8.0% Inpatient All Surgical 6.0% Outpatient 4.0% 2.0% 0.0% Source: Patient discharge data from the hospital research database maintained by the Prem

  18. Slide 18: Increasing utilization per patient

    Increasing utilization per patient OFIRMEV ® Vial UtilizationSurgical - Inpatient Procedures (Premier Healthcare Alliance Database) 3.50 3.25 3.00 2.75 2.50 2.25 2.00 Source: Patient discharge data from the hospital research database maintained by the Premier healthcare alliance (October 10, 2013) S

  19. Slide 19: Long term opportunity

    Long term opportunity Physicians indicate higher expectations for future use of OFIRMEV® Projected Future Use (% of patients treated) 60% 55% 42% 43% Anesthesiologists Surgeons Sep 2011 Survey Dec 2012 Survey Question (September 2011): What percentage of your (surgical procedures) would you expect t

  20. Slide 20: Long term opportunity: ketorolac as a case study

    Long term opportunity: ketorolac as a case study Benchmarking potential future use of OFIRMEV® against ketorolac utilization Limitations of NSAIDs Perioperative Pain Population High Risk of Bleeding Perioperative pain population Contraindicated as prophylactic analgesic prior to any major surgery Ca

  21. Slide 21: Long term opportunity: share of patients

    Long term opportunity: share of patients Physicians project OFIRMEV® to be much more broadly utilized than NSAIDs Projected OFIRMEV Use IV Analgesic Use in Surgical Inpatients (ATU Market Research**) (Premier Hospital Database*) 92% 56% 25% 12% MD Projection of OFIRMEV OFIRMEV Q2 2013 NSAIDs OPIOIDS

  22. Slide 22: Long term opportunity: doses per patient

    Long term opportunity: doses per patient Physicians project significant increases in doses per patient Doses Per Patient – Inpatient Surgery (July 2013 Survey) 6.1 4.3 3.4 2.2 Current Use Projected Use Current Use Projected Use (July 2013) in 3yrs (July 2013) in 3yrs Anesthesiologists Surgeons (n=43

  23. Slide 23: Delivering sustainable growth

    Delivering sustainable growth • Continueto broadenanddeepenuseof OFIRMEV® in treatingpost-oppain – Current trends and primary market research indicate potential for sustained growth in patient share and vials per patient • Support implementation of multi-modal pain management strategies to help hosp

  24. Slide 24: Business development: target profile

    Business development: target profile Accelerate growth by leveraging Cadence’s existing infrastructure through acquisitions of products or companies Near Term Long Term Region US US / Global* Channel Hospital Hospital** • Moderate-large marketed or ready- Product Status & • Modest sized marketed or

  25. Slide 25: Financial highlights

    Financial highlights 12 mos. ended 9 mos. ended 12/31/12 9/30/13 (in MM) (in MM) Net product revenue $50.1 $77.2 Operating expenses $103.6 $75.4 Cash, cash equivalents & $62.1 $54.3 short-term investments Shares outstanding 85.7 86.1 25

  26. Slide 26: Investment highlights

    Investment highlights • Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting – OFIRMEV® (acetaminophen) injection –Indicated for use in adults and children >2yrs for the: • Management of mild to moderate pain • Manag

  27. Slide 27: Important Safety Information about OFIRMEV (acetaminophen) injection

    Important Safety Information about OFIRMEV® (acetaminophen) injection WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death. OFIRMEV contains acetamin

Cadence Pharmaceuticals — Investor Presentation (December 2013) on 6ix